[{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Harrow \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Apotex Inc"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclica \/ Arctoris","highestDevelopmentStatusID":"1","companyTruncated":"Cyclica \/ Arctoris"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"CyPA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"CyPA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"CyPA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Pennsylvania \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"University of Pennsylvania \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"||CyPA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Newport Pharmaceuticals","sponsor":"WellSpring","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Newport Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Newport Pharmaceuticals \/ WellSpring","highestDevelopmentStatusID":"4","companyTruncated":"Newport Pharmaceuticals \/ WellSpring"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SGN Nanopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Eyenovia \/ SGN Nanopharma","highestDevelopmentStatusID":"1","companyTruncated":"Eyenovia \/ SGN Nanopharma"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"Zhaoke Ophthalmology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke Ophthalmology \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Harrow"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"||Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Entod Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Entod Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Entod Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Wellspring Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Wellspring Ophthalmics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Wellspring Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wellspring Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huons CO., LTD \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Huons CO., LTD \/ Lupin Ltd"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Concord Biotech","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||IMPDH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Concord Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concord Biotech \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Concord Biotech \/ Lupin Ltd"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||IMPDH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Restasis
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
